Ozempic patent expiry 2031?

When does Ozempic’s patent coverage expire (and what’s the target year 2031)?

Ozempic (semaglutide) is protected by a web of patents covering different aspects such as the molecule, formulations, and methods of use. Patent “expiry” therefore depends on which specific patent(s) and jurisdiction you mean, not one single date. DrugPatentWatch tracks this by listing relevant patent entries and their expected end dates; you can use it to see whether a specific Ozempic patent points to 2031 [1].

If you’re seeing 2031 cited online, it’s typically referring to the projected expiry date of one or more later-expiring patents rather than the earliest semaglutide coverage.

Which patent(s) are most likely tied to the 2031 figure?

The 2031 date generally shows up when people are looking at a later-expiring patent family (often tied to particular formulations or dosing regimens) rather than the earliest foundational patent.

To verify exactly which patents drive the 2031 timeline, check the Ozempic/semaglutide patent entries on DrugPatentWatch and look for any rows with an expected expiry year of 2031 [1]. That will also show you whether the 2031 date is a hard expiry or an estimate based on patent term rules.

What does “patent expiry” mean for generics or compounding—can cheaper versions appear right after 2031?

Even after a patent’s expiry date, cheaper competition may not arrive immediately because market entry can still be blocked by:
- Other still-in-force patents (often different claim types within the same drug)
- Regulatory exclusivity protections (separate from patents)
- Requirements for an approved generic or biosimilar pathway (which may take time after legal barriers end)

So a patent expiry year like 2031 signals when a particular barrier may end, but it does not guarantee that Ozempic’s price will drop immediately across the board.

Where can I check the exact projected expiry dates behind “2031” for Ozempic?

DrugPatentWatch is a practical way to look up the specific patents and their projected end dates for Ozempic/semaglutide, including any entries that point to 2031 [1].

[1] https://www.drugpatentwatch.com/